- 7028 malaria professionals are enjoying the free benefits of MalariaWorld today

Who's online
There are currently 5 users and 226 guests online.
Online users
- Events
- ric.ataide
- KleinE
- epivec
- krijnpaaijmans
News Flash
Latest Jobs
Events 2010
Recent blog posts
- Announcement: Malaria Course Ifakara 2012 (English)
- Job: Postdoctoral Fellow: Malaria transmission-blocking research (Entomologist/Malariologist)
- Job: ACT Consortium Policy Liaison Officer
- Harnessing Immunity Genes Against Plasmodium: The Series
- We thought we were down to 655.000 deaths in 2010, right?
- Job: Postdoctoral Fellow: Malaria resistance research
- Let the sun shine
- Postdoctoral Fellows: Malaria research
- Guest Editorial: Don't fake it!
- Loop mediated amplification question
Analysis of gene mutation and amplification were performed by nested real-time polymerase chain reaction and SYBR Green I real-time polymerase chain reaction, respectively.
The speed at which ASAQ Winthrop was adopted in the field shows that this drug fits the needs of patients and health authorities.
DHA/PQP was a highly efficacious drug for P. falciparum malaria in areas where multidrug parasites are prevalent. The DHA/PQP combination can play an important role in the first-line treatment of uncomplicated falciparum malaria.
Pediatric drug formulations of artemisinin combination therapies are urgently needed for improving the treatment of children suffering from uncomplicated malaria. The aim of this clinical trial was to evaluate the efficacy, safety and tolerability of a novel pediatric fixed-dose granule formulation of artesunate-mefloquine and a new co-blister tablet formulation.